![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, December 09, 2009 6:29:06 PM
Now that the merger is complete, I would anticipate the following
steps to be taken next:
The Selection of a manufacturing agent to build the product in accordance with Sam Lee's specifications.
Once working models are built, selecting a marketing / sales team
to promote the product to interested parties on a national and international level while concurrently submitting to the FDA for approval.
I would imagine that FDA approval (for human use applications)
could possibly take a year or two, until then, the product could
probably be marketed outside the US in some regions for human use.
The product could be used in the US on animals without FDA approval but I would suspect the medical industry would not be
willing to embrace the use of this product until we have FDA approval.
I am looking forward to seeing the Bioharp story unfold and wish
the best to all investors, please post any thoughts you may have
on how you see the process unfolding from here. Thanks in advance.
GLTA
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM